Specialised Therapeutics to Commercialize Incyte's Opzelura in Australia
Specialised Therapeutics has expanded its partnership with Incyte Biosciences International, an affiliate of Incyte Corporation (INCY), to register and commercialize ruxolitinib cream—marketed as Opzelura—in Australia. The product is already approved for use in the U.S. and EU under the brand name Opzelura at a concentration of 1.5%. This agreement marks another step in Specialised Therapeutics' strategy to expand its portfolio through partnerships with global biopharmaceutical firms. The deal highlights Incyte's ongoing efforts to extend the commercial reach of ruxolitinib cream, which is used for treating eczema and other inflammatory skin conditions. For Specialised Therapeutics, this partnership enhances their market presence in Australia by leveraging an established product from a reputable biopharma company.
Tickers: $INCY